ZURA BIO LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.38 USD | -9.38% |
|
-10.34% | -27.62% |
| 14/06 | Zura Bio Presents Data for the Tibulizumab (Zb-106) Program At Eular 2024 | CI |
| 06/06 | Zura Bio Limited Announces Formation of a Scientific Advisory Board | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 203.6 | 213.2 | - | - |
| Enterprise Value (EV) 1 | 203.6 | 213.2 | 213.2 | 213.2 |
| P/E ratio | -2.23 x | -6.56 x | -4.25 x | -3.61 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 51.2 x |
| EV / Revenue | - | - | - | 51.2 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -6.88 x | -5.02 x | -3.71 x |
| FCF Yield | - | -14.5% | -19.9% | -27% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 43,594 | 62,326 | - | - |
| Reference price 2 | 4.670 | 3.420 | 3.420 | 3.420 |
| Announcement Date | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | 4.167 |
| EBITDA | - | - | - | - |
| EBIT 1 | -62.64 | -40.13 | -61.11 | -80.29 |
| Operating Margin | - | - | - | -1,926.85% |
| Earnings before Tax (EBT) 1 | -60.56 | -37.05 | -57.76 | -76.61 |
| Net income 1 | -60.36 | -33.55 | -57.76 | -76.61 |
| Net margin | - | - | - | -1,838.65% |
| EPS 2 | -2.090 | -0.5217 | -0.8050 | -0.9467 |
| Free Cash Flow 1 | - | -31 | -42.5 | -57.5 |
| FCF margin | - | - | - | -1,380% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -33.9 | -10.19 | -10.83 | -8.379 | -9.126 | -10.28 | -12.3 | -12.96 | -14.19 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -34.02 | -8.27 | -8.473 | -7.747 | -8.509 | -9.299 | -11.32 | -11.85 | -13.04 |
| Net income 1 | -9.592 | -44.9 | -8.27 | -8.473 | -7.747 | -8.509 | -9.299 | -11.32 | -11.85 | -13.04 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -1.310 | -0.1800 | - | -0.0200 | -0.1500 | -0.1483 | -0.1767 | -0.1667 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/05/23 | 14/08/23 | 13/11/23 | 28/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -31 | -42.5 | -57.5 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 2.54 | 2.55 | 2.55 |
| Capex / Sales | - | - | - | 61.2% |
| Announcement Date | 28/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.42
USD
Average target price
17.8
USD
Spread / Average Target
+420.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.62% | 213M | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +8.24% | 23.61B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B |
- Stock Market
- Equities
- ZURA Stock
- Financials Zura Bio Limited
